Lenalidomide: Clinical Trials

20 trials of Lenalidomide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 5 unknown, 3 recruiting, 2 not yet recruiting. 20 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 420Completed 5, Unknown 5, Recruiting 3, Not yet recruiting 2, Terminated 2, Withdrawn 2, Active not recruiting 1

Follow Lenalidomide: new trials by email Literature Review of Lenalidomide trials Research Report on Lenalidomide

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen
Sotoclax, Carfilzomib, Lenalidomide - Newly Diagnosed Multiple Myeloma, T(11;14)
Phase 4Not yet recruitingThe First Affiliated Hospital of Soochow University202026-07-012026-07-17
Isa-VRD in TIE HRMM
Isatuximab, bortezomib, lenalidomide, dexamethason, Bortezomib, Lenalidomide, Dexamethasone - Multiple Myeloma
Phase 4Not yet recruitingPeking Union Medical College Hospital1172026-01-302026-01-13
Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)
Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet, Bortezomib + Lenalidomide + Dexamethasone - Peripheral Neuropathy, Multiple Myeloma, Neoplasms
Phase 4RecruitingTanta University442025-08-302025-11-04
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
Carfilzomib, Daratumumab, Lenalidomide - Newly Diagnosed, High Risk
Phase 4RecruitingThe First Affiliated Hospital of Soochow University592024-06-122025-06-12
Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS
Lenalidomide, Azacitidine - Myelodysplastic Syndromes
Phase 4UnknownPeking Union Medical College Hospital1382023-08-012023-08-22
Immunomodulators on HIV-1 Reservoir
Lenalidomide, Adenosylmethionine - HIV Infections
Phase 4UnknownFirst Affiliated Hospital of Zhejiang University482022-11-202023-09-14
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Ixazomib plus low-dose lenalidomide, Ixazomib - Multiple Myeloma
Phase 4RecruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine1002022-07-012026-01-05
A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
Ixazomib, Pomalidomide, Lenalidomide - Multiple Myeloma
Phase 4WithdrawnTakeda2022-06-302022-05-03
Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial
Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5., Placebo - COVID-19
Phase 4UnknownHospital Universitario Getafe1202020-10-272020-07-31
Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients
Bortezomib 3.5 MG - Newly Diagnosed Multiple Myeloma
Phase 4WithdrawnAl-Rasheed University College2020-03-012023-04-28
Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
Ixazomib, Lenalidomide - Multiple Myeloma
Phase 4CompletedPeking Union Medical College Hospital2112019-09-242024-08-01
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Drug: Carfilzomib + Dexamethasone, Drug: Carfilzomib + Lenalidomide + Dexamethasone - Relapsed Refractory Multiple Myeloma
Phase 4CompletedAmgen1012019-09-162026-05-11
PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma
PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine - Peripheral T-cell Lymphoma
Phase 4UnknownMingzhi Zhang1002019-09-012020-05-12
PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma
PD-1 Antibody, chidamide, lenalidomide and etoposide - NK/T Cell Lymphoma
Phase 4UnknownMingzhi Zhang502019-04-012019-07-30
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
Velcade, Melphalan, Prednisone - Multiple Myeloma
Phase 4Active not recruitingUniversity of Turin, Italy4502019-01-032025-12-03
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
Ixazomib, Bortezomib, Carfilzomib - Relapsed and/or Refractory Multiple Myeloma
Phase 4CompletedTakeda452018-02-182022-09-27
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
Ixazomib, Lenalidomide, Dexamethasone - Multiple Myeloma
Phase 4TerminatedTakeda1412017-11-132026-05-04
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
Autologous peripheral blood stem cell transplant, Lenalidomide, Dexamethasone - Multiple Myeloma
Phase 4CompletedColumbia University602012-09-012020-02-05
LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)
Lenalidomide - AML
Phase 4TerminatedPETHEMA Foundation42011-01-012014-04-07
Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus
Lenalidomide - Cutaneous Lupus
Phase 4CompletedHospital Universitari Vall d'Hebron Research Institute152010-01-012011-08-03

Conditions studied

Multiple Myeloma (10)  ·  COVID-19 (1)  ·  HIV Infections (1)  ·  Lymphoma, Extranodal NK-T-Cell (1)  ·  Lymphoma, T-Cell, Peripheral (1)  ·  Myelodysplastic Syndromes (1)  ·  Neoplasms (1)  ·  Peripheral Nervous System Diseases (1)

Sponsors

Peking Union Medical College Hospital (3)  ·  Takeda (3)  ·  Mingzhi Zhang (2)  ·  The First Affiliated Hospital of Soochow University (2)  ·  Al-Rasheed University College (1)  ·  Amgen (1)  ·  Columbia University (1)  ·  First Affiliated Hospital of Zhejiang University (1)  ·  Hospital Universitari Vall d'Hebron Research Institute (1)  ·  Hospital Universitario Getafe (1)  ·  PETHEMA Foundation (1)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)  ·  Tanta University (1)  ·  University of Turin, Italy (1)

Countries

China (9)  ·  Spain (3)  ·  United States (2)  ·  Egypt (1)  ·  India (1)  ·  Iraq (1)  ·  Italy (1)  ·  Japan (1)

Top investigators

Adil S Al-Oqaby, PhD (1)  ·  Alaaldin S Naji, PhD (1)  ·  Ali M Jawad, PhD (1)  ·  Ammer F Majid, PhD (1)  ·  Ashraf M Alaa, BSc of clinical pharmacy (1)  ·  Bassam F Matti, PhD (1)  ·  Biao Zhu (1)  ·  Hawraa D Jumaa, PhD (1)  ·  Hayder A Fawzi, PhD (1)  ·  Joaquin De Haro, MD (1)  ·  Junling Zhuang (1)  ·  Junling Zhuang, MD (1)

Results publications

PMID 23217273, PMID 37341778, PMID 37807952

NIH funding

2009 (1)